Price
$4.54
Increased by +4.13%
Dollar Volume (20D)
10.24 M
ADR%
8.35
Earnings Report Date (estimate)
Feb 26, 24
Shares Float
109.32 M
Shares Outstanding
168.28 M
Shares Short
23.09 M
Market Cap.
763.98 M
Beta
0.72
Price / Earnings
N/A
20D Range
3.12 5.08
50D Range
2.25 5.08
200D Range
2.23 6.89
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Nov 2, 23 -0.37
Increased by +36.21%
-0.52
Increased by +28.85%
Aug 2, 23 -0.53
Decreased by -1.92%
-0.59
Increased by +10.17%
May 3, 23 -0.68
Decreased by -21.43%
-0.62
Decreased by -9.68%
Feb 28, 23 -0.66
Decreased by -22.22%
-0.7
Increased by +5.71%
Nov 2, 22 -0.58
Decreased by -1.75%
-0.64
Increased by +9.38%
Aug 9, 22 -0.52
Increased by +1.89%
-0.61
Increased by +14.75%
May 4, 22 -0.56
Decreased by -124%
-0.58
Increased by +3.45%
Feb 23, 22 -0.54
Decreased by -1.89%
-0.6
Increased by +10%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 23 43 K
Decreased by -12.24%
-61.31 M
Increased by +25.36%
Decreased by -142.59 K%
Increased by +14.94%
Jun 30, 23 44 K
Decreased by -48.84%
-77.99 M
Decreased by -4.72%
Decreased by -177.25 K%
Decreased by -104.69%
Mar 31, 23 52 K
Decreased by -14.75%
-98.34 M
Decreased by -23.37%
Decreased by -189.11 K%
Decreased by -44.73%
Dec 31, 22 47 K
Decreased by -7.84%
-93.32 M
Decreased by -24.65%
Decreased by -198.55 K%
Decreased by -35.25%
Sep 30, 22 49 K
Increased by 0%
-82.15 M
Decreased by -5.06%
Decreased by -167.64 K%
Decreased by -5.06%
Jun 30, 22 86 K
Increased by +95.45%
-74.47 M
Decreased by -4.98%
Decreased by -86.6 K%
Increased by +46.29%
Mar 31, 22 61 K
Decreased by -99.84%
-79.71 M
Decreased by -141.43%
Decreased by -130.67 K%
Decreased by -151.66 K%
Dec 31, 21 51 K
Increased by +N/A%
-74.87 M
Decreased by -9.18%
Decreased by -146.8 K%
Decreased by N/A%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO- 316, an allogeneic CAR T cell product candidates for the treatment of immune checkpoint inhibitor; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.